Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia

Chronic myeloid leukemia was the first haematological neoplasia that benefited from a targeted therapy with imatinib nearly 15 years ago. Since then, several studies have investigated the role of genes, their variants (i.e., polymorphisms) and their encoded proteins in the pharmacokinetics and pharm...

Descripción completa

Detalles Bibliográficos
Autores principales: Polillo, Marialuisa, Galimberti, Sara, Baratè, Claudia, Petrini, Mario, Danesi, Romano, Di Paolo, Antonello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613337/
https://www.ncbi.nlm.nih.gov/pubmed/26402671
http://dx.doi.org/10.3390/ijms160922811

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613337/
https://www.ncbi.nlm.nih.gov/pubmed/26402671
http://dx.doi.org/10.3390/ijms160922811

Ejemplares similares